An inevitable consequence is that, before using small- or broad-spectrum MMP-9 inhibitors in SLE patients, careful preclinical evidence of efficiency needs to be provided and sufficient safety measures will be needed in clinical trials. Here, MMP9 is linked to systemic lupus erythematosus.